CMMB — Chemomab Therapeutics Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1534248 ·
Israel
Last close
$2.16
Market Cap
$15.83M
52W High
$3.58
52W Low
$1.35
ADV30
110,987
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,241,000 | -2,165,000 | 10,238,000 | 5,999,000 | 1,553,000 |
| Mar 2026 | 0 | — | -1,850,000 | -1,773,000 | 11,808,000 | 5,906,000 | 1,113,000 |
| Dec 2025 | 0 | — | -1,974,000 | -1,873,000 | 13,812,000 | 7,564,000 | 1,478,000 |
| Sep 2025 | 0 | — | -1,844,000 | -1,742,000 | 12,368,000 | 6,974,000 | 1,137,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-113,391,000
Inventory
—
Receivables
$3,431,000
ST Investments
$2,137,000
EBIT TTM
$-7,930,000
Pretax Income TTM
$-7,445,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,567,000 | -8,995,000 | 13,812,000 | 1,478,000 | 12,334,000 | -11,130,000 |
| Dec 2024 | 0 | -14,739,000 | -13,945,000 | 16,964,000 | 3,427,000 | 13,537,000 | -15,386,000 |
| Dec 2023 | 0 | -25,459,000 | -24,221,000 | 22,151,000 | 5,154,000 | 16,997,000 | -23,611,000 |
| Dec 2022 | 0 | -28,533,000 | -27,646,000 | 43,063,000 | 6,840,000 | 36,223,000 | -20,370,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTXR | Citius Pharmaceuticals, Inc. | $15.90M | $0.58 | — |
| LTRN | Lantern Pharma Inc. | $15.60M | $1.22 | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $16.33M | $0.68 | — |
| ALLR | Allarity Therapeutics, Inc. | $16.39M | $1.03 | — |
| DARE | Dare Bioscience, Inc. | $15.26M | $0.78 | — |
News headlines (Yahoo Finance, 1h cache)
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-19 12:26 · Yahoo
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
2026-07-08 11:35 · Yahoo
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 12:00 · Yahoo
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
2026-08-31 12:00 · Yahoo
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
2026-03-19 12:00 · Yahoo
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026-02-17 13:00 · Yahoo
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
2025-12-02 13:00 · Yahoo
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
2025-11-24 13:00 · Yahoo
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
2025-10-23 14:27 · Yahoo
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
2025-10-22 14:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.